Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18861649 | 0.84 | CYP3A4 (0.36) | HDAC8CYP3A4CYP2D6PSEN1PSEN2 | |
| SCHEMBL20621292 | 0.80 | CHRNA7 (0.33) | CHRNA7LMNAJAK2KDRAURKA | |
| SCHEMBL2904251 | 0.80 | TYR (0.43) | HDAC8CYP3A4CHRNA7LMNAJAK2 | |
| SCHEMBL6638838 | 0.77 | TYR (0.34) | HDAC8CYP3A4CHRNA7LMNAJAK2 | |
| SCHEMBL3256436 | 0.77 | ROCK1 (0.37) | HDAC8CYP3A4CYP2D6PSEN1PSEN2 | |
| SCHEMBL19769033 | 0.76 | L3MBTL1 (0.50) | CHRNA7JAK2TYRTRPA1PTGS1 | |
| SCHEMBL24450487 | 0.74 | CHRNA7 (0.33) | CHRNA7 | |
| SCHEMBL1282140 | 0.72 | — | — | |
| SCHEMBL4878671 | 0.72 | LMNA (0.35) | HDAC8CYP3A4CHRNA7LMNAJAK2 | |
| SCHEMBL9756953 | 0.72 | KDM4E (0.51) | HDAC8CYP3A4LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10544106-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190292178-A9 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9879003-B2 | Host targeted inhibitors of dengue virus and other viruses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-18 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544106-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | HDAC8 929/4885CYP3A4 1264/4885CYP2D6 1933/4885 |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL17, RPL26, RPL35 | HDAC8 1597/4885CYP3A4 4071/4885CYP2D6 2492/4885 |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | HDAC8 2646/4885CYP3A4 3550/4885CYP2D6 2924/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HDAC8 1458/4885CYP3A4 275/4885CYP2D6 956/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | HDAC8 1603/4885CYP3A4 2948/4885CYP2D6 2808/4885 |
| US-20190292178-A9 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL26, RPL35, RPL5 | HDAC8 2344/4885CYP3A4 3158/4885CYP2D6 2098/4885 |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | HDAC8 929/4885CYP3A4 1264/4885CYP2D6 1933/4885 |
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | HDAC8 606/4885CYP3A4 4840/4885CYP2D6 4817/4885 |
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | HDAC8 2646/4885CYP3A4 3550/4885CYP2D6 2924/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | HDAC8 681/4885CYP3A4 4681/4885CYP2D6 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.